SCHEMBL1010657

SCHEMBL1010657

O=[N+]([O-])c1ccc(C(F)(F)F)c(F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.53
HIF1A Q16665 2/20 0.53
PDE7A Q13946 1/20 0.51
POLB P06746 1/20 0.49
SLC6A9 P48067 1/20 0.45
SLC6A5 Q9Y345 1/20 0.45
KMT2A Q03164 4/20 0.44
KIF11 P52732 5/20 0.44
TSHR P16473 2/20 0.43
LMNA P02545 2/20 0.43
MEN1 O00255 3/20 0.43
MAPT P10636 2/20 0.43
HSD17B10 Q99714 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
FFAR4 Q5NUL3 1/20 0.42
NPC1 O15118 1/20 0.42
STAT3 P40763 1/20 0.42
MTOR P42345 1/20 0.42
RAB9A P51151 1/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30619304 1.00 ALDH1A1 (0.53) ALDH1A1HIF1APDE7APOLBSLC6A9
SCHEMBL6050910 0.85 ALDH1A1 (0.50) ALDH1A1HIF1APDE7APOLBKMT2A
SCHEMBL28350522 0.85 ALDH1A1 (0.50) ALDH1A1HIF1APDE7APOLBKMT2A
SCHEMBL11197012 0.85 ALDH1A1 (0.53) ALDH1A1HIF1APDE7AKMT2ATSHR
SCHEMBL85544 0.85 ALDH1A1 (0.58) ALDH1A1HIF1APDE7APOLBKMT2A
SCHEMBL1999857 0.84 PDE7A (0.54) ALDH1A1HIF1APDE7APOLBKMT2A
SCHEMBL2031510 0.83 ALDH1A1 (0.52) ALDH1A1HIF1APDE7AKMT2ATSHR
SCHEMBL20940166 0.83 ALDH1A1 (0.52) ALDH1A1HIF1APDE7AKMT2ATSHR
SCHEMBL8147133 0.81 ALDH1A1 (0.58) ALDH1A1HIF1APDE7APOLBKMT2A
SCHEMBL27797067 0.80 ALDH1A1 (0.49) ALDH1A1HIF1APDE7AKMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743085-A2 COMPOUNDS, COMPOSITIONS, AND METHODS Tenvie Therapeutics, Inc. (US) 2026-05-20 EP disclosed
WO-2026098560-A2 BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2026-05-15 WO disclosed
WO-2025019357-A2 COMPOUNDS, COMPOSITIONS, AND METHODS NICO THERAPEUTICS, INC. (US) 2025-01-23 WO disclosed
CN-111196804-B TGF-beta R1 inhibitors and uses thereof 南京圣和药业股份有限公司 2023-11-07 CN disclosed
US-20230227409-A1 QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. 2023-07-20 US disclosed
WO-2021252681-A1 QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2021-12-16 WO disclosed
CN-111196804-A TGF- β R1 inhibitor and application thereof 南京圣和药业股份有限公司 2020-05-26 CN disclosed
CN-110746424-A MK2 inhibitors and uses thereof 西建卡尔有限责任公司 2020-02-04 CN disclosed
US-20190135835-A1 MK2 INHIBITORS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2019-05-09 US disclosed
US-10138256-B2 MK2 inhibitors and uses thereof CELGENE CAR LLC (BM) 2018-11-27 US disclosed
WO-2002089792-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO disclosed
WO-2002090353-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO disclosed
WO-2002089740-A2 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO disclosed
WO-2002089793-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO disclosed
US-4411912-A Insecticidal isovaleric acid esters ZOECON CORPORATION (US) 1983-10-25 US disclosed
US-4243819-A Substituted amino acids ZOECON CORPORATION (US) 1981-01-06 US disclosed
US-4224340-A Anti-inflammatory compositions containing α-phenyl-N-phenylnitrone compounds WILLIAM H. RORER, INC. (US) 1980-09-23 US disclosed
US-4214003-A ANTIINFLAMMATORY AGENTS WILLIAM H. RORER, INC. (US) 1980-07-22 US disclosed
US-4197314-A WITH A DIPHENYL NITRONE WILLIAM H. RORER, INC. (US) 1980-04-08 US disclosed
US-4153722-A ANTIINFLAMMATORY, A-PHENYL-N-PHENYLNITRONE WILLIAM H. RORER, INC. (US) 1979-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227409-A1 QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS MAT2B, MAT2A, MAT1A ALDH1A1 607/4885HIF1A 2434/4885PDE7A 490/4885
US-10138256-B2 MK2 inhibitors and uses thereof MKNK2, DUSP2, MKNK1 ALDH1A1 4078/4885HIF1A 4667/4885PDE7A 2000/4885
US-20190135835-A1 MK2 INHIBITORS AND USES THEREOF MKNK2, DUSP2, MKNK1 ALDH1A1 4078/4885HIF1A 4667/4885PDE7A 2000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.